BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma

Gobin, B., Baud'Huin, M., Lamoureux, F. et al. (8 more authors) (2015) BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. International Journal of Cancer, 136 (4). pp. 784-796. ISSN 0020-7136

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2014 UICC
Keywords: osteosarcoma; osteoblast; osteoclast; vascularization; PI3K; mTOR
Dates:
  • Published: 15 February 2015
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 19 May 2016 13:38
Last Modified: 03 Nov 2016 17:49
Published Version: http://dx.doi.org/10.1002/ijc.29040
Status: Published
Publisher: John Wiley & Sons
Identification Number: https://doi.org/10.1002/ijc.29040
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)